Biotechnology companies in Illinois are pivotal in unlocking health solutions, emphasizing research and product innovation to tackle diseases. They range from startups working on groundbreaking gene therapies to established firms focused on drug development and diagnostics. The industry thrives on collaboration, harnessing local academic institutions and venture funding to navigate challenges in healthcare. Moreover, artificial intelligence and micro-biomics are emerging trends, enhancing personalized medicine to align treatment options with individual patient needs. As the demand for effective therapies grows, Illinois positions itself as a hub for biotech companies at the forefront of scientific advancements.

The companies listed here reflect the vibrant biotechnology sector in Illinois, showcasing a mix of sizes and specializations. Most operate around Chicago, with others in Naperville and Schaumburg, founded between the 1970s and the 2020s. These firms concentrate on various areas including immunotherapies, genomics, and medical devices. While some companies are focused on gene technology, others emphasize research services or diagnostic advancements. Overall, Illinois boasts both established players and agile startups aiming to craft effective solutions to meet pressing health challenges.

Read on to explore notable biotechnology companies in Illinois.

Top 23 Biotechnology Companies in Illinois

1. ARCH Venture Partners

• Website: archventure.com
• Ownership type: Private
• Headquarters: Chicago, Illinois, United States (USA)
• Employee distribution: United States (USA) 97%, Ireland 3%
• Founded year: 1986
• Headcount: 11-50
• LinkedIn: arch-venture-partners

ARCH Venture Partners, founded in 1986 and based in Chicago, Illinois, is a private venture capital firm that specializes in biotechnology investments. With a team of experienced professionals, ARCH provides not only funding but also strategic support to early-stage biotech companies. Their mission is to catalyze discoveries that prevent, detect, and cure diseases. ARCH is known for its deep involvement with portfolio companies, offering guidance and leveraging its extensive network to help these firms navigate the complexities of bringing new technologies to market. Their portfolio includes a range of innovative companies focused on groundbreaking medical solutions, showcasing their commitment to advancing the life sciences sector. Although they have not reported any recent funding rounds, their ongoing initiatives and partnerships reflect their active role in shaping the future of biotechnology.

2. Evozyne

• Website: evozyne.com
• Ownership type: Venture Capital
• Headquarters: Chicago, Illinois, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series B, $81.0M, September 2023
• Founded year: 2020
• Headcount: 51-200
• LinkedIn: evozyne

Evozyne, founded in 2020 and based in Chicago, Illinois, is a biotechnology company dedicated to developing novel protein systems aimed at solving critical health challenges. The company specializes in creating high-performance therapeutic proteins and gene editing technologies, collaborating with pharmaceutical companies to enhance drug development processes. Evozyne employs generative AI and evolutionary principles to design adaptive proteins, which are essential for addressing complex medical issues. Their product pipeline includes therapeutics such as IgG proteases that modulate immune responses and a portfolio of high-performance CRISPR gene editors. Evozyne has secured significant funding, with their latest round raising $81 million in September 2023, reflecting strong investor interest in their innovative approach. The company’s partnerships with industry leaders like NVIDIA and Takeda further underscore its commitment to advancing therapeutic solutions and addressing unmet medical needs.

3. Paragon Biosciences

• Website: paragonbiosci.com
• Ownership type: Private
• Headquarters: Chicago, Illinois, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $185.0M, November 2022
• Founded year: 2010
• Headcount: 11-50
• LinkedIn: paragon-biosciences-llc

Paragon Biosciences, based in Chicago, Illinois, is a biotechnology firm founded in 2010. The company specializes in creating, building, and funding innovative biology-based companies aimed at addressing unmet medical needs. Paragon focuses on developing treatments across various medical conditions, particularly within the life sciences sector. Their portfolio includes companies like Emalex Biosciences, which is advancing therapies for central nervous system disorders, and Evozyne, which utilizes generative AI for drug discovery. Paragon's commitment to innovation is underscored by their recent funding round, where they secured $185 million in November 2022, further enabling their mission to accelerate scientific breakthroughs and improve patient outcomes.

4. Jaguar Gene Therapy

• Website: jaguargenetherapy.com
• Ownership type: Venture Capital
• Headquarters: Lake Forest, Illinois, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: March 2022
• Founded year: 2019
• Headcount: 51-200
• LinkedIn: jaguargenetherapy

Jaguar Gene Therapy, based in Lake Forest, Illinois, is a biotechnology firm established in 2019. The company is dedicated to developing innovative gene therapies aimed at treating severe genetic diseases. They utilize advanced manufacturing processes and AAV-based delivery systems to create therapies that are both safe and effective. Their focus is on addressing the root causes of genetic disorders, which is critical for improving health outcomes for affected individuals and families. Jaguar Gene Therapy is currently advancing a pipeline of gene therapies targeting conditions such as galactosemia, severe neurodevelopmental disorders linked to the SHANK3 gene, and Type 1 diabetes. The company collaborates with Advanced Medicine Partners to ensure high-quality manufacturing processes, which is essential for the successful development and delivery of their therapies. With a team of experts experienced in gene therapy, Jaguar is positioned to make significant contributions to the biotechnology industry.

5. OMX Ventures

• Website: omx.vc
• Ownership type: Private
• Headquarters: Chicago, Illinois, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 2020
• Headcount: 1-10
• LinkedIn: omx-ventures

OMX Ventures, based in Chicago, Illinois, is a private venture capital firm founded in 2020. The firm specializes in investments within the life sciences and biotechnology sectors, providing both funding and strategic support to early-stage companies. OMX Ventures aims to empower scientists and innovators who are pushing the boundaries of biological research and product development. Their portfolio features a range of startups focused on various aspects of biotechnology, including molecular detection, synthetic biology, and therapeutics. The team at OMX Ventures comprises professionals with backgrounds in biology, engineering, and finance, allowing them to offer comprehensive support to the companies they invest in. They emphasize a collaborative approach, acting as thought partners and allies to the founders they work with, which enhances the potential for success in the biotechnology space.

6. Cour Pharmaceuticals Development Co., Inc.

• Website: courpharma.com
• Ownership type: Venture Capital
• Headquarters: Skokie, Illinois, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series A, $105.0M, January 2024
• Founded year: 2015
• Headcount: 11-50
• LinkedIn: cour-pharmaceutical-development-company-inc.

Cour Pharmaceuticals Development Co., Inc., founded in 2015 and based in Skokie, Illinois, is a biotechnology firm dedicated to developing first-in-class therapies that aim to reprogram the immune system for the treatment of autoimmune diseases. The company leverages a proprietary nanoparticle platform designed to induce antigen-specific tolerance, which could provide a more effective solution for conditions such as Myasthenia Gravis, Primary Biliary Cholangitis, Type 1 Diabetes, and Celiac Disease. Cour's lead product, CNP-101, partnered with Takeda, represents a significant milestone as it is the first investigational agent to demonstrate the induction of antigen-specific immune tolerance in any autoimmune disease. The company is currently advancing its clinical trials, including a Phase 2a study for CNP-104, which has shown positive results. With a recent funding round of $105 million, Cour is well-positioned to continue its research and development efforts in the biotechnology sector.

7. Xentria, Inc.

• Website: xentria.com
• Ownership type: Private
• Headquarters: Chicago, Illinois, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $25.0M, October 2022
• Founded year: 2020
• Headcount: 11-50
• LinkedIn: xentria-inc

Xentria, Inc., founded in 2020 and based in Chicago, Illinois, is a biotechnology company dedicated to innovative drug development and collaboration within the life sciences sector. The company specializes in creating therapeutics for rare diseases, with a particular focus on pulmonary sarcoidosis. Xentria's services extend to clinical trial management and regulatory guidance, aimed at addressing significant gaps in healthcare. Their lead candidate, XTMAB-16, is currently undergoing clinical trials and has received Orphan Drug Designation from both the FDA and the European Medicines Agency, highlighting its potential to meet critical medical needs. With a small team of around 24 employees, Xentria is actively engaged in partnerships that enhance their research and development efforts, demonstrating a commitment to advancing healthcare solutions. In October 2022, they secured $25 million in funding, which underscores their growth potential and the interest of investors in their mission.

8. Sparx Biopharmaceutical CORP

• Website: sparxbio.com
• Ownership type: Private
• Headquarters: Mount Prospect, Illinois, United States (USA)
• Employee distribution: United States (USA) 71%, China 29%
• Founded year: 2018
• Headcount: 51-200
• LinkedIn: sparx-therapeutics

Sparx Biopharmaceutical CORP, founded in 2018 and based in Mount Prospect, Illinois, is a private biopharmaceutical company dedicated to the development of innovative antibody therapies and immuno-oncology agents. The company aims to strengthen human immunity through advanced research and development, targeting multiple pathways in cancer treatment. Sparx employs sophisticated technologies, including their proprietary SAILING™ and SYNMAB™ platforms, to discover and optimize multi-specific antibodies. Their pipeline includes several candidates, such as SPX-303, which has recently received FDA approval for an Investigational New Drug application. With a team of experienced professionals from notable pharmaceutical backgrounds, Sparx is positioned to make significant contributions to the field of oncology and antibody therapeutics.

9. Proteintech Group

• Website: ptglab.com
• Ownership type: Private
• Headquarters: Rosemont, Illinois, United States (USA)
• Employee distribution: United States (USA) 48%, United Kingdom (UK) 25%, Germany 10%, Other 16%
• Founded year: 2001
• Headcount: 201-500
• LinkedIn: proteintech-group

Proteintech Group, Inc. is a biotechnology firm based in Rosemont, Illinois, founded in 2001. The company specializes in the development and manufacturing of high-quality antibodies, immunoassays, and proteins tailored for both research and clinical applications. With a workforce of approximately 213 employees, Proteintech serves a global clientele, including researchers and laboratories in the life sciences sector. Their products are essential for ensuring accurate and reproducible results in scientific studies. The company also offers custom services to cater to specific research needs, demonstrating their adaptability and commitment to supporting the scientific community. Proteintech has expanded its product range to include cGMP-grade proteins, which are crucial for clinical applications, and has a notable presence in various research areas such as cancer, immunology, and neuroscience. Their focus on quality and customer service has helped them build a loyal customer base, making them a relevant player in the biotechnology industry.

10. Vanqua Bio

• Website: vanquabio.com
• Ownership type: Venture Capital
• Headquarters: Chicago, Illinois, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $45.0M, July 2024
• Founded year: 2019
• Headcount: 11-50
• LinkedIn: vanqua-bio

Vanqua Bio, based in Chicago, Illinois, is a biopharmaceutical company established in 2019. The company is dedicated to developing next-generation medicines aimed at treating neurodegenerative diseases, with a particular focus on Parkinson's disease and Alzheimer's disease. Vanqua Bio employs a unique drug-development strategy that leverages insights into neuronal cell pathways and advanced screening techniques. Their lead program targets glucocerebrosidase (GCase), a critical enzyme linked to Parkinson's disease, and they are also exploring therapies that address immune system overactivation in various neurological disorders. The company has attracted significant venture capital funding, with a recent round totaling nearly $45 million in July 2024, underscoring its potential in the biopharmaceutical sector. Vanqua Bio's commitment to transforming patient care through innovative therapies positions it as a noteworthy player in the biotechnology industry.

11. SmartHealth Catalyzer, Inc.

• Website: smarthealthcatalyzer.com
• Ownership type: Private
• Headquarters: Riverwoods, Illinois, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 2019
• Headcount: 1-10
• LinkedIn: smarthealthcatalyzer

SmartHealth Catalyzer, Inc., founded in 2019 and based in Riverwoods, Illinois, operates as a biomedical venture studio. The company specializes in building startups around promising biomedical research emerging from Midwest universities and research hospitals. Their services include venture creation, commercialization of therapeutics, diagnostics, and medical devices, as well as support in intellectual property protection and technology transfer. SmartHealth Catalyzer collaborates with elite bioentrepreneurs and biotech experts, each with over 30 years of industry experience, to accelerate the development of innovative solutions aimed at addressing life-threatening diseases. Their portfolio includes companies like Saros Therapeutics, which focuses on cancer treatment, and Covira Surgical, which aims to improve infection control in surgical settings. By connecting research institutions with investors, SmartHealth Catalyzer plays a pivotal role in transforming scientific discoveries into viable market solutions.

12. BiomeSense

• Website: biomesense.com
• Ownership type: Venture Capital
• Headquarters: Chicago, Illinois, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $6.2M, December 2023
• Founded year: 2018
• Headcount: 1-10
• LinkedIn: biomesense

BiomeSense, founded in 2018 and based in Chicago, Illinois, is a biotechnology company that specializes in microbiome data generation and analysis. The company has developed advanced technologies, including GutLab Technology and the MetaBiome AI Platform, which enable continuous tracking and analysis of microbiome data. This innovation addresses the prevalent issue of limited data availability in microbiome research, facilitating a deeper understanding of host-microbiome interactions. BiomeSense partners with scientists and organizations in clinical research, focusing on personalized medicine and biomarker discovery. The company has recently secured funding, amounting to over $6 million, which underscores its active role in the industry and its potential for growth. With a small team of dedicated professionals, BiomeSense is poised to make significant contributions to the field of microbiome science and its applications in health and disease.

13. Ihma

• Website: ihma.com
• Ownership type: Private
• Headquarters: Schaumburg, Illinois, United States (USA)
• Employee distribution: United States (USA) 82%, Switzerland 16%, India 3%
• Founded year: 1992
• Headcount: 51-200
• LinkedIn: ihma-inc

International Health Management Associates (Ihma) is a private biotechnology firm based in Schaumburg, Illinois, founded in 1992. The company specializes in the development of antimicrobial drugs, providing a suite of services that includes drug discovery, clinical microbiology, and regulatory support. Ihma assists pharmaceutical companies and organizations in the intricate process of developing effective antimicrobial therapies, ensuring compliance with regulatory standards. Their expertise extends to conducting pre-clinical studies, global laboratory services for clinical trials, and antimicrobial resistance surveillance. With a dedicated team of clinical microbiologists and scientists, Ihma offers tailored solutions to meet the unique needs of their clients, facilitating the successful commercialization of new therapies. Their Bacterial Repository is a key asset, housing a collection of characterized bacterial pathogens that aids in profiling the antibacterial activities of products in development. Ihma's commitment to addressing antimicrobial resistance positions them as a vital partner in the biotechnology industry.

14. Orochem Technologies, Inc.

• Website: orochem.com
• Ownership type: Private
• Headquarters: Naperville, Illinois, United States (USA)
• Employee distribution: United States (USA) 71%, India 29%
• Latest funding: Other (Grant), $225,000, June 2016
• Founded year: 1996
• Headcount: 11-50
• LinkedIn: orochem-technologies-inc-usa

Orochem Technologies, Inc., founded in 1996 and based in Naperville, Illinois, is a biotechnology company that specializes in chromatography and bioanalytical sample preparation. The company manufactures a wide array of products aimed at improving efficiency and purity in drug discovery and genomic research. Their offerings include advanced sample preparation techniques, chromatography columns, and high-throughput lab automation systems. Orochem also provides contract services and technical support, catering to the needs of pharmaceutical and research clients. With a strong emphasis on innovation, Orochem has developed proprietary technologies and holds several patents in the field. The company has a notable presence in both the U.S. and India, reflecting its global reach in the biotechnology market.

15. Genective

• Website: genective.com
• Ownership type: Private
• Headquarters: Champaign, Illinois, United States (USA)
• Employee distribution: United States (USA) 95%, France 5%
• Founded year: 2011
• Headcount: 11-50
• LinkedIn: genective

Genective is a biotechnology company based in Champaign, Illinois, founded in 2011. The company specializes in agricultural biotechnology, focusing on the research and development of transgenic corn traits, particularly those that enhance pest resistance. As a joint venture between Groupe Limagrain and KWS Group, two of the largest seed companies globally, Genective leverages significant expertise and resources in the agricultural sector. The company collaborates with various agricultural businesses and organizations to improve crop productivity and sustainability. With a small team of around 37 employees, Genective operates primarily in the United States, with a minor presence in France. Their commitment to high standards in scientific research and stewardship is evident in their operations, and they are recognized as a member of Excellence Through Stewardship®, which underscores their dedication to responsible biotechnology practices.

16. Biologos

• Website: biologos.com
• Ownership type: Private Equity
• Headquarters: Glendale Heights, Illinois, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: March 2024
• Founded year: 1976
• Headcount: 11-50
• LinkedIn: biologos-llc

Biologos, founded in 1976 and based in Glendale Heights, Illinois, is a private equity-backed manufacturer specializing in biologics. The company focuses on custom cell culture media, buffers, and reagents, catering primarily to the biopharma and diagnostics industries. With a commitment to quality and customer satisfaction, Biologos ensures rapid delivery and flexibility in its product offerings. Their operations are certified under ISO 13485:2016 and comply with cGMP standards, reflecting their dedication to high-quality manufacturing processes. Biologos serves a range of sectors, including cell and gene therapy, diagnostics, and animal health, positioning itself as a trusted partner in advancing healthcare solutions. The company has recently relocated to a state-of-the-art facility, further enhancing its capabilities to meet the evolving needs of its clients.

17. Experimur, A Frontage Company

• Website: experimur.com
• Ownership type: Private
• Headquarters: Chicago, Illinois, United States (USA)
• Founded year: 2000
• Headcount: 11-50
• LinkedIn: experimur

Experimur, A Frontage Company, based in Chicago, Illinois, is a private laboratory services provider founded in 2000. With a workforce of around 32 employees, the company specializes in a comprehensive suite of drug development and testing services tailored for pharmaceutical and biotechnology firms. Their offerings include drug discovery, drug metabolism and pharmacokinetics (DMPK), safety assessment, and clinical trial support. Experimur plays a pivotal role in helping clients manage the intricate processes involved in bringing new drugs to market. Their commitment to scientific research and regulatory compliance is evident in their extensive service portfolio, which includes both in vitro and in vivo testing, as well as specialized toxicology services. This focus on supporting drug development underscores their importance in the biotechnology sector.

18. Boston Bioprocess

• Website: bostonbioprocess.com
• Ownership type: Venture Capital
• Headquarters: Champaign, Illinois, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Seed, $6.3M, July 2024
• Founded year: 2022
• Headcount: 11-50
• LinkedIn: boston-bioworks

Boston Bioprocess, based in Champaign, Illinois, is a biotechnology service provider that specializes in fermentation and downstream processing. Founded in 2022, the company aims to assist biotech and pharmaceutical companies in scaling up their production capabilities. Their services include fermentation optimization, which enhances yield through strain testing and media optimization, and downstream process development to minimize product loss. They also offer regulatory guidance to navigate the complexities of FDA approvals. With a team of around 20 employees, Boston Bioprocess has already established partnerships with notable organizations, such as the Integrated Bioprocessing Research Laboratory at the University of Illinois and Cauldron, to support fermentation-based companies in their transition from lab to manufacturing. The company has successfully secured $6.26 million in seed funding as of July 2024, reflecting a strong interest in their innovative approach to bioprocessing.

19. Dimension Inx

• Website: dimensioninx.com
• Ownership type: Venture Capital
• Headquarters: Chicago, Illinois, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Other (Grant), $75,000, February 2025
• Founded year: 2017
• Headcount: 11-50
• LinkedIn: dimension-inx

Dimension Inx is a biomedical company based in Chicago, Illinois, founded in 2017. The company specializes in designing and developing therapeutic products that aim to restore tissue and organ function. With a focus on innovative biomaterials, Dimension Inx collaborates with various partners to tackle complex challenges in regenerative medicine. Their product pipeline addresses multiple therapeutic applications, including musculoskeletal health and soft tissue restoration. The company prides itself on its interdisciplinary team, which combines expertise in materials science, biomedical engineering, and advanced manufacturing. This allows them to quickly iterate on multifunctional therapeutic products and accelerate their commercialization. Dimension Inx has also received funding, including a recent grant of $75,000 in February 2025, which underscores the ongoing interest in their work and potential for future growth.

20. Hematogenix

• Website: hematogenix.com
• Ownership type: Private
• Headquarters: Tinley Park, Illinois, United States (USA)
• Employee distribution: United States (USA) 34%, United Kingdom (UK) 33%, Malaysia 30%, Other 2%
• Founded year: 2007
• Headcount: 51-200
• LinkedIn: hematogenix

Hematogenix is a private laboratory services company based in Tinley Park, Illinois, founded in 2007. With a workforce of approximately 165 employees, the company specializes in cancer diagnostics and treatment. Hematogenix offers advanced testing and pathology services, primarily catering to pharmaceutical and biotech companies, as well as oncologists. Their expertise includes hematopathology, solid tumor pathology, minimal residual disease (MRD) testing, companion diagnostics, next-generation sequencing (NGS), and immuno-oncology. The company is recognized for its commitment to quality, holding multiple certifications such as CAP accreditation and CLIA certification. Hematogenix operates globally, with facilities in North America, Europe, China, and Asia-Pacific, providing essential support for clinical trials and the development of novel therapies. Their focus on patient-centric care and rapid turnaround times enhances their relevance in the biotechnology field.

21. Meitheal Pharmaceuticals, Inc.

• Website: meithealpharma.com
• Ownership type: Private
• Headquarters: Chicago, Illinois, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Other (Debt), $35.0M, August 2023
• Founded year: 2017
• Headcount: 51-200
• LinkedIn: meitheal-pharmaceuticals-inc.

Meitheal Pharmaceuticals, Inc., founded in 2017 and based in Chicago, Illinois, is a biopharmaceutical company dedicated to developing and commercializing affordable medications. The company specializes in generics, biologics, and fertility treatments, aiming to enhance access to essential medicines for healthcare providers and patients. Meitheal's mission revolves around delivering impactful products through both internal development and strategic partnerships. Their product pipeline includes several biosimilars and biologics, such as insulin products for diabetes and therapies for oncology and autoimmune diseases. Recently, Meitheal announced the acquisition of YUSIMRY®, marking their entry into the biosimilars market. With a workforce of approximately 106 employees, the company is positioned to make significant contributions to the biopharmaceutical landscape. In August 2023, Meitheal secured $35 million in funding, further supporting their initiatives to bring innovative healthcare solutions to market.

22. Pathos

• Website: pathos.com
• Ownership type: Venture Capital
• Headquarters: Chicago, Illinois, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series C, $62.0M, October 2024
• Founded year: 2022
• Headcount: 11-50
• LinkedIn: pathos-ai

Pathos is a biotechnology company based in Chicago, Illinois, founded in 2022. The company specializes in drug development and precision medicine, with a strong emphasis on oncology. Pathos utilizes advanced AI technologies to refine patient selection and improve the effectiveness of clinical-stage therapeutics. Their proprietary PathOS Platform™ integrates extensive real-world oncology data and patient-derived functional genomic data, allowing them to identify and validate biological insights that traditional methods might overlook. Pathos actively partners with biopharmaceutical companies to revitalize shelved programs and accelerate the development of effective cancer treatments. Recently, they raised $62 million in Series C funding, which underscores their growth potential and the industry's interest in their innovative approach to drug development.

23. Nucleai

• Website: nucleai.ai
• Ownership type: Venture Capital
• Headquarters: Chicago, Illinois, United States (USA)
• Employee distribution: Israel 84%, United States (USA) 16%
• Latest funding: $14.0M, April 2024
• Founded year: 2018
• Headcount: 51-200
• LinkedIn: nuclai

Nucleai, founded in 2018 and based in Chicago, Illinois, is a biotechnology company that specializes in AI-driven spatial biomarkers and diagnostics. The company aims to transform patient care by providing innovative solutions for biomarker discovery, scoring, and genomic screening. Nucleai's technology leverages advanced AI methods to analyze complex cellular interactions in biopsy samples, translating these insights into actionable data that can accelerate drug development and improve treatment decisions. Their primary clientele includes biopharmaceutical companies and clinical researchers, highlighting their role in the drug development process. Nucleai has recently secured $14 million in funding as of April 2024, reflecting strong investor confidence in their mission to enhance precision medicine and tackle significant healthcare challenges.

Biotechnology Insights: Key Companies in Illinois

Want to Find More Biotechnology Companies?

With Inven you'll also get to know the company's:

• Detailed Ownership: Who owns the company? Is it a public or private company? What is the ownership structure?
• Contact data: Who are the founders and CEO's? What are their emails and phone numbers?
• Financials: How do these companies perform financially? What are their revenues and profit margins?

...and a lot more!